



Kinase Inhibitors 2021

Guest Editor:

Prof. Dr. Pascal Marchand

Cibles et Médicaments des
Infections et de L'immunité,
IICiMed, UR 1155, Nantes
Université, F-44000 Nantes,
France

Deadline for manuscript
submissions:

closed (31 July 2021)

Message from the Guest Editor

Dear Colleagues,

In the last decade, about 300 protein kinase inhibitors have been involved in clinical trials and 49 were recently approved by the US Food and Drug Administration (FDA), mostly tyrosine kinase inhibitors, and mainly for cancer therapy. In the same period, targeting kinase pathways has emerged as a promising strategy in the fight against infectious diseases that are caused by pathogenic microbes such as bacteria, viruses, parasites, or fungi. Protein kinase inhibitors were also considered as potential drugs to combat CNS disorders.

This Special Issue will showcase the recent trends in the field of drug discovery of kinase inhibitors. In addition, review articles, research articles, and short communications will highlight the efforts of medicinal chemists to propose new molecules endowed with kinase inhibition properties and the strategies to enhance the activity profile of the existing pipeline.

Repurposing human kinase inhibitors also gained attention to create new active compounds.

Prof. Dr. Pascal Marchand

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical
Biology and Phytochemistry,
University of Münster,
Corrensstrasse 48, D-48149
Münster, Germany

Message from the Editor-in-Chief

As the premier open access journal dedicated to molecular chemistry, now in its 30th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts, and novel materials. Pushing the boundaries of the discipline, we invite papers on all major fields of molecular chemistry and multidisciplinary topics bridging chemistry with biology, physics, and materials science, as well as timely reviews and topical issues on cutting-edge fields in all of these areas.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Reaxys](#), [CaPlus / SciFinder](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

Journal Rank: JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Contact Us

Molecules Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/molecules
molecules@mdpi.com
[X@Molecules_MDPI](#)